Comparison
GHRP-6 vs Semax
Side-by-side of GHRP-6 and Semax. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.
GHRP-6
First-generation hexapeptide ghrelin-receptor agonist. Pioneered the GHS-R1a pathway in the 1980s. Produces the strongest hunger response among GHRPs and a mo.
Semax
Semax peptide benefits: nootropic ACTH(4-10) analog without corticotropic activity. Cognitive enhancement, neuroprotection, intranasal dosing, Russian stroke.
Effects at a glance
GHRP-6
- •First-generation hexapeptide ghrelin-receptor agonist; foundational to the GHRP class
- •Strongest appetite stimulation of any synthetic GHRP at equivalent GH doses
- •Produces measurable cortisol and prolactin rise alongside the GH pulse
- •Anecdotal protocols use 100 to 200 mcg subcutaneously 2 to 3 times daily on an empty stomach
- •Largely superseded by ipamorelin (cleaner profile) and GHRP-2 (stronger pulse) for body-composition use
- •Banned by WADA under S2; detection methods validated in accredited labs
Semax
- •Synthetic heptapeptide analog of ACTH(4-10) developed in Russia in the 1980s
- •Approved in Russia for ischemic stroke, cognitive impairment, and cerebrovascular disorders
- •Lacks the corticotropic activity of native ACTH due to the Pro-Gly-Pro stabilizing tail
- •Russian RCTs report improved cognitive recovery in acute ischemic stroke versus standard care
- •Modulates BDNF and NGF expression and dopaminergic signaling in preclinical models
- •Standard route is intranasal; not FDA approved; research-use-only outside Russia
Side-by-side
| Attribute | GHRP-6 | Semax |
|---|---|---|
| Category | peptide | peptide |
| Also known as | Growth Hormone Releasing Peptide 6, SKF-110679, Histidyl-D-Tryptophyl-Alanyl-Tryptophyl-D-Phenylalanyl-Lysinamide | Met-Glu-His-Phe-Pro-Gly-Pro, ACTH(4-10) Pro-Gly-Pro analog |
| Half-life (hr) ↗ | 0.5 | 0.5 |
| Typical dose (mg) ↗ | 0.1 | 0.6 |
| Dosing frequency | 2-3x daily | 2-3x daily (intranasal) |
| Routes | subcutaneous, intravenous | intranasal |
| Onset (hr) | 0.25 | 0.5 |
| Peak (hr) | 0.5 | 2 |
| Molecular weight | 872.44 | 813.94 |
| Molecular formula | C46H56N12O6 | C37H51N9O10S |
| Mechanism | Hexapeptide agonist of GHS-R1a (ghrelin receptor). Suppresses hypothalamic somatostatin and stimulates pituitary somatotrophs, with strong central NPY/AgRP appetite signaling and modest cortisol and prolactin release. | Modulates BDNF and NGF expression in hippocampus and cortex, enhances dopaminergic and serotonergic signaling, and reduces oxidative stress markers in preclinical ischemia models. Lacks corticotropic activity of native ACTH. |
| Legal status | Not FDA approved; research-use-only grey market; banned by WADA | Approved in Russia for stroke and cognitive disorders; not FDA approved; research-use-only grey market elsewhere |
| WADA status | banned | unknown |
| DEA / Rx | Not scheduled (research chemical) | Not FDA approved; not scheduled; research-chemical status outside Russia |
| Pregnancy | Insufficient data; not recommended | Not recommended; insufficient data |
| CAS | 87616-84-0 | 80714-61-0 |
| PubChem CID | 9919072 | 9811102 |
| Wikidata | Q5519921 | Q4413083 |
Safety profile
GHRP-6
Common side effects
- intense hunger
- water retention
- vivid dreams
- head pressure or flushing
- tingling at injection site
- transient lethargy
Contraindications
- pregnancy
- active malignancy
- history of pituitary tumor
- uncontrolled diabetes
- prolactin sensitivity
Interactions
- CJC-1295: synergistic GH release; commonly co-administered(minor)
- sermorelin: additive GH release via parallel GHRH and ghrelin pathways(minor)
- insulin: sustained GH can blunt insulin sensitivity over weeks(moderate)
- corticosteroids: blunt GH response and amplify cortisol load(moderate)
Semax
Common side effects
- mild nasal irritation
- transient mild headache
- rare mild euphoria or activation
Contraindications
- pregnancy
- lactation
- acute psychotic disorder
- severe hypertension (caution due to mild activating effect)
Interactions
- stimulants (caffeine, amphetamines): potential additive activation; monitor for overstimulation(minor)
- antipsychotics: theoretical antagonism via dopaminergic modulation(minor)
Which Should You Take?
GHRP-6 comes out ahead for most readers on the criteria we weight: 3 catalogued goals, research-only / gray-market sourcing, with a Tier-B outcome catalogued. Semax is the right call when one of the conditionals below applies.
- → If your priority is growth-hormone axis, pick GHRP-6.
- → If your priority is appetite regulation, pick GHRP-6.
- → If your priority is focus or working memory, pick Semax.
- → If your priority is long-term neuroprotection, pick Semax.
Default choice: GHRP-6. Wider use case, and broader goal coverage. Reach for Semax only if your priority sits squarely in the goals it owns above.
This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.
Common questions
What is the difference between GHRP-6 and Semax?
GHRP-6 and Semax differ in category (peptide vs peptide), mechanism, and typical dosing. See the side-by-side table for full details.
Which has a longer half-life, GHRP-6 or Semax?
GHRP-6 half-life is 0.5 hours; Semax half-life is 0.5 hours.
Can you stack GHRP-6 with Semax?
Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.
Go deeper